Free Trial

Compass Therapeutics (CMPX) News Today

$1.08
+0.04 (+3.85%)
(As of 07/12/2024 ET)
Compass Therapeutics logo with Medical background
Compass Therapeutics (NASDAQ:CMPX) Shares Up 0.7%
Compass Therapeutics (NASDAQ:CMPX) Trading 0.7% Higher
Braidwell LP Has $496,000 Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)
Braidwell LP cut its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 94.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 317,761 shares of the company's stock after selling
HC Wainwright Reiterates Buy Rating for Compass Therapeutics (NASDAQ:CMPX)
HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Monday.
Monashee Investment Management LLC Has $780,000 Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)
Monashee Investment Management LLC decreased its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 59.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 500,000 shares of the com
Compass Therapeutics Announces CEO Transition
HC Wainwright Weighs in on Compass Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Compass Therapeutics in a research note issued to investors on Tuesday, May 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per sh
Compass Therapeutics (NASDAQ:CMPX) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Tuesday.
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Tuesday.
Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Decline in Short Interest
Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,620,000 shares, a drop of 13.8% from the March 15th total of 1,880,000 shares. Approximately 2.0% of the company's stock are short sold. Based on an average daily volume of 485,500 shares, the days-to-cover ratio is currently 3.3 days.
Compass Therapeutics' (CMPX) "Outperform" Rating Reaffirmed at Wedbush
Wedbush reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Friday.
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Thursday.
Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Declines By 6.6%
Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a significant decrease in short interest in February. As of February 29th, there was short interest totalling 1,840,000 shares, a decrease of 6.6% from the February 14th total of 1,970,000 shares. Based on an average daily volume of 527,500 shares, the days-to-cover ratio is presently 3.5 days. Approximately 2.4% of the company's shares are short sold.
Fmr LLC Decreases Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)
Fmr LLC lowered its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 17.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,553,093 shares of the company's stock after selling 982,413 shares du
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Monashee Investment Management LLC
Monashee Investment Management LLC lowered its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 37.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,226,142 shares of the company's stock after selling 743,15
Leerink Partnrs Comments on Compass Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Compass Therapeutics in a research note issued on Monday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will p
Compass Therapeutics Inc Ordinary Shares
Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 8.1%
Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,270,000 shares, an increase of 8.1% from the December 15th total of 2,100,000 shares. Based on an average daily volume of 514,700 shares, the days-to-cover ratio is presently 4.4 days. Currently, 2.8% of the company's stock are short sold.
Compass Therapeutics Provides Corporate Update
Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update
Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 2,100,000 shares, a decline of 21.3% from the November 30th total of 2,670,000 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average trading volume of 356,400 shares, the short-interest ratio is presently 5.9 days.
Compass Therapeutics Insider Ups Holding During Year
TD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)
Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

Anyone can do this, rich and poor alike (Ad)

I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.

Watch now

CMPX Media Mentions By Week

CMPX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CMPX
News Sentiment

0.87

0.89

Average
Medical
News Sentiment

CMPX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CMPX Articles
This Week

4

1

CMPX Articles
Average Week

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CMPX) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners